182 results about "Neutralization" patented technology

The invention relates to an anti-H7N9 full-human-derived monoclonal antibody 5J13 and a preparation method and application thereof. Amino acid sequences of heavy and light chain CDR1, CDR2 and CDR3 of the antibody are GFSFSNYG in the heavy chain CDR1 area, ISYDGTNK in the heavy chain CDR2 area, AKGRGPYCSSSICYHGMDV in the heavy chain CDR3 area, QSVLSGSINMNY in the light chain CDR1 area, WAS in the light chain CDR2 area and QQYYSTPLT in the light chain CDR3 area correspondingly. The antibody can be combined with hemagglutinin A of the H7N9virus in a targeted mode and has remarkable neutralization activity in resisting H7N9 virus infection. Compared with a murine antibody, genes of the full-human-derived antibody are completely from human genes and have no components of other species, toxic and side effects such as the anti-mouse anti-antibody are avoided, the biocompatibility is better, and the anti-H7N9 full-human-derived monoclonal antibody 5J13 is more suitable and has more potential in becoming a macromolecular drug for treating influenza virus.

Diagnostic methods comprise measuring specifically the level of at least one iso-eosinophilic cationic protein (iso-ECP) in a sample from an individual to be diagnosed, and comparing the measured level of the iso-ECP with a predetermined level of the iso-ECP. The iso-ECP is cytotoxic and the cytotoxicity of the iso-ECP is not capable of neutralization by the monoclonal antibodies EG1 and EG2. Anti-iso-ECP antibody which may be used in the diagnostic methods specifically binds to a cytotoxic isoform of ECP having an epitope which is unique for the native form of the cytotoxic iso-ECP.

The invention discloses a completely humanized neutralizing antibody for anti-rabies viruses. The amino acid sequence of a heavy chain of the antibody is shown in sequence table SEQ ID NO1, the amino acid sequence of a light chain of the antibody is shown in sequence table SEQ ID NO5, the complementary determining region (CDR) of a variable region of the heavy chain of the antibody is shown as follows: CDR1: SEQIDNO2, CDR2:SEQIDNO3 and CDR3: SEQIDNO4, and the complementary determining region (CDR) of a variable region of the light chain of the antibody is shown as follows: CDR1:SEQIDNO6, CDR2:SEQIDNO7, and CDR3: SEQIDNO8. The beneficial effects of the completely humanized neutralizing antibody are that: the completely humanized neutralizing antibody disclosed by the invention ahs the advantages of being completely humanized, good in specificity, high in affinity, good in neutralizing effect, and low in price, can be used as a biological engineering antibody drug to quickly establish immune protection force against rabies virus, can be used for passive immunotherapy of acute infection, and also can be used for preparing detection reagents for detecting the rabies virus, finding effective neutralization antigen epitope and developing recombinant proteins and subunit vaccines for the rabies virus.

The application relates to an anti-H7N9 full human derived monoclonal antibody hIg311 and a preparation method and application thereof. A memory B cell PCR method is used for quickly screening a fullhuman derived monoclonal antibody hIg311, and the anti-H7N9 human derived monoclonal antibody hIg311 is free from any mouse derived components. The antibody disclosed by the application can realize target combination of hemagglutinin HA of H7N9 viruses, and has notable anti H7N9 viral infection neutralization activity. The antibody disclosed by the application does not generate toxic and side effects for resisting mouse resisting antibodies, has good biocompatibility, and is suitable for becoming and has potential to become macromolecular drugs for treating influenza viruses.

The invention provides a method for detecting canine rabies virus antibody (IgG) and a detection kit. The kit is composed of a coated plate and a reagent reaction system, and comprises a rabies virus antigen-coated reaction plate, a standard substance, positive contrast serum, a washing lotion (20X), a sample weak solution, an enzyme-marked combination substance, a developer A, a developer B and a stopping solution. The method is characterized in that the method uses an ELISA method to determine that the content of the canine rabies virus antibody (IgG) reaches a absorbance corresponding to a protective level by detecting the standard substance of the kit, and by compared the absorbance of the sample to be detected with the absorbance of the standard substance, the content of the canine rabies virus antibody (IgG) contained in the sample to be detected is judged whether to reach an immunization protective level. The method and the kit can simultaneously detect a lot of samples, and a detection result is remarkably with a result by a neutralization experiment, has high accuracy degree, is suitable for monitoring an immunization inoculation effect and determining an individual immunization state, and can be used for investigating animal eqpidemic diseases.

The present inventors developed hepatitis C virus 1a/2a and 1b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a/2a and 1b/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis. The inventors in addition demonstrate the use of the developed systems for screening of antiviral substances in vitro and functional studies of the virus, e.g. identification of receptors required for HCV entry

A scalable process and device for producing a bio molecule, in particular pharmaceutical grade plasmid DNA is described. The process includes the steps of alkaline lysis, neutralization and clarification and can be further extended. For separating the lysate and the precipitate an improved floatation method is disclosed. This method is based on attachment of CO₂ bubbles on the precipitate floe. The CO₂ is released from a carbonate salt during or after neutralization (acidification). The method of the invention is preferably carried out in an automated continuous mode applying devices for lysis and neutralization and a novel device for completely continuous clarification (separation of floes and clarified lysate).

The invention provides a fully humanized anti-tetanus bispecific antibody. The bispecific antibody includes a single-stranded unit A and a single-stranded unit B, both the single-stranded units A andB contain a single-stranded variable fragment (scFv), a human IgG1 hinge region and an Fc fragment, wherein the scFv of the single-stranded unit A has specific binding ability to a region centered onTrp 1289 of tetanus toxoid, and the scFv of the single-stranded unit B has specific binding ability to a region centered on Arg1216 of the tetanus toxoid. The invention also provides a construction method and application of the bispecific antibody. After neutralization experiments in mice, results show that the antibody has a neutralizing protection effect, and the bispecific antibody can be usedas a diagnostic reagent to detect the quality of a tetanus toxoid antigen, and can replace the tetanus antitoxin, equine tetanus immunoglobulin or human tetanus immunoglobulin to be used for passive immunization.

The invention provides a novel humanized coronavirus neutralizing active antibody and application thereof. According to the novel humanized coronavirus neutralizing active antibody, the monoclonal antibody with neutralizing activity is separated and screened from the body of a rehabilitation patient infected by the novel coronavirus, has excellent affinity and specificity to the novel coronavirus(SARS-CoV-2), and can effectively block the combination of the novel coronavirus and receptor protein.

The invention discloses a humanized single-chain antibody 8B of clostridium perfringens alpha-toxin. The humanized single-chain antibody 8B is screened from a phage antibody library Source bioscience, is a full-humanized antibody of the clostridium perfringens alpha-toxin and can be used for achieving a toxin neutralization treating effect, overcoming various side effects of a heterologous antibody and eliminating complex steps and high cost of humanization modification on the heterologous antibody; and the single-chain antibody is small in molecular weight, strong in in-vivo penetrability and capable of rapidly reaching to damaged tissues and cells to exert an antitoxin effect, so that the double aims of economy and high efficiency are achieved. The alpha-toxin has a certain homology with other types of toxins of clostridium perfringens, so that the antibody drug possibly generates inhibiting and treating effects for other types of toxins and can also be used as a detecting reagent to detect the clostridium perfringens alpha-toxin.

The invention discloses a humanized antibody for resisting avian influenza H5N1 hemagglutinin (HA) antigen. A heavy chain variable region of the humanized antibody has an amino acid sequence shown in SEQ ID No.1; a light chain variable region of the humanized antibody has an amino acid sequence shown in SEQ ID No.2. In addition, the invention also discloses a preparation method and application of the humanized antibody. The humanized antibody is extensive and widespread in coagulation inhibition activity for avian influenza H5N1 virus, high in affinity and neutralization activity for various subtypes of the HA antigen of the avian influenza H5N1, and capable of recognizing a special conserved region of one H5HA; the humanized antibody is high in neutralization activity and capable of reducing immunogenicity; a recognized epitope is highly conserved in the H5 type influenza virus; the humanized antibody is extensive in application prospect in prevention and treatment and vaccine design of the avian influenza H5N1 in the future.

The invention relates to an antigenic epitope of spring viraemia of carp and belongs to the technical field of biology. According to the invention, by virtue of phage display technique, a positive clone is screened out by the use of spring viraemia of carp virus (SVCV) monoclonal antibody, a conserved sequence binding to the SVCV monoclonal antibody is found out, a clinical diagnosis reagent is prepared by the screened antigenic epitope, and spring viraemia of carp is prevented and treated by a small molecular antigen peptide as a vaccine. The gene sequence of the invention is SEQ ID NO:1. The phage display technique is utilized to screen the positive clone by SVCV monoclonal antibody and find out the conserved sequence which can bind to the monoclonal antibody with the ability of SVCV activity neutralization in a random peptide library. The site of the antigenic determinant is determined, and the relationship of its sequence, structure and function is analyzed. The study of inhibition effect to SVCV generated from the competitive binding of small peptide to SVCV receptor will have a huge application value for taking small molecular antigen peptide as vaccine in the future.

The invention discloses a monoclonal antibody for neutralizing novel coronavirus infection. The invention provides the antibody. The amino acid sequence of a light chain variable region of the antibody is the 1-110th site of a sequence 2 in a sequence listing; and the amino acid sequence of a heavy chain variable region of the antibody is the 1-120th site of a sequence 4 in the sequence listing. The monoclonal antibody N5 is identified to have higher binding specificity and affinity to the S protein RBD (receptor binding domain) of the novel coronavirus, and an in vitro neutralization experiment shows that the N5 can effectively neutralize the infection activity of the novel coronavirus SARS-CoV-2. On the basis, the gene sequence of the N5 antibody is measured, then recombinant expression is carried out, and the expressed recombinant antibody also has the neutralizing activity of the SARS-CoV-2.

The invention belongs to the technical field of fluorescent probes, and provides a fluorescent probe for quantitatively detecting riboflavin on the basis of a fluorescence resonance energy transfer ratio, and a preparation method and an application for the fluorescent probe. The preparation method comprises the following steps: with glucose as a carbon source, ethylenediamine as a nitrogen source,concentrated phosphoric acid as a phosphorus source and concentrated hydrochloric acid as a chlorine source, preparing nitrogen-phosphorus-chlorine co-doped carbon quantum dots (NPCl-CQDs) through anacid-base neutralization reaction exothermic carbonization method, dissolving NPCl-CQDs powder into ultrapure water, carrying out centrifuging to remove insoluble substances, carrying out filtering to remove impurities, and carrying out freeze-drying so as to obtain the fluorescent probe, namely NPCl-CQDs solid powder. The linear relationship between a riboflavin concentration and an NPCl-CQDs fluorescence intensity is determined by using a ratio fluorescence detection method. The content of riboflavin in an actual sample is detected through a standard recovery experiment, and a standard recovery rate is calculated. The method provided by the invention is simple and convenient to operate, low in background interference, high in sensitivity, free of expensive instruments and equipment, lowin detection cost, capable of rapidly, efficiently and quantitatively detecting the content of the riboflavin in an actual sample in a ratio and good in reproducibility.

The invention relates to broad spectrum neutralization monoclonal antibodies and antigen binding fragments thereof, which can combine with human papilloma virus (HPV) L2 protein and neutralize a plurality of types of HPV, coding of the sequences of the monoclonal antibodies and the antigen binding fragments thereof, generation of cell strains of the monoclonal antibodies and the antigen binding fragments thereof, and methods and applications of the monoclonal antibodies and the antigen binding fragments thereof on diagnosis, prevention, and treatment. The invention also relates to epitope peptides, which the broad spectrum neutralization monoclonal antibodies aim at, a carrier protein containing the epitope peptides, and applications of the epitope peptides and the carrier protein.

A recombinant antibody against the enterovirus '71' contains the amino acid sequence shown by SED ID No.14,15,16,17,18,19,20,21,22,23,24,25, or 26 or its active analog. A process for obtaining said antibody includes such steps as choosing the yeast cell from yeast antibody library for expressing said antibody, culturing it, and collecting said antibodies from the cultured substance. A process for preparing said antibody includes such steps as culturing the host cells in the condition that the antibody is expressed, and collecting the antibodies from the cultured substances.